As access to medicines expands worldwide, low- and middle-income countries (LMICs) face the challenge of ensuring these therapies remain safe, effective, and properly monitored. Pharmacovigilance (PV) systems in these regions are rapidly evolving ,but gaps in infrastructure, resources, and training can make consistent safety monitoring difficult.
To achieve true global drug safety, equitable pharmacovigilance capacity-building must be a shared priority for regulators, healthcare organisations, and industry stakeholders alike.
Current Challenges in LMIC Pharmacovigilance
Many LMICs are still in the early stages of building national PV frameworks, often relying on limited data collection systems and manual processes. Common challenges include:
- Underreporting of adverse events, due to limited awareness among healthcare professionals.
- Lack of standardised systems for data capture, analysis, and reporting.
- Insufficient regulatory harmonisation across regions.
- Limited training and resources for pharmacovigilance professionals.
- Dependence on global partners for technical and audit support.
Without robust PV infrastructure, safety signals can go unnoticed, delaying critical interventions and eroding patient confidence.
Building Resilient and Sustainable PV Systems
To strengthen PV frameworks in LMICs, a comprehensive and collaborative approach is essential. Key focus areas include:
- Capacity Building and Training:
Developing local expertise through structured training programmes ensures long-term sustainability.Regulators and MAHs should invest in continuous learning for PV staff, investigators, and healthcare professionals. - Digital Transformation
Adoption of electronic reporting tools, cloud-based safety databases, and AI-supported systems can dramatically improve efficiency and reporting accuracy. - Regulatory Harmonisation
Alignment with WHO, ICH, and regional PV guidelines promotes consistent safety monitoring and facilitates global data sharing. - Partnerships and Technical Support
Collaboration with experienced PV service providers, such as Q&V, can help design and implement quality systems that meet both local and international requirements.
The Role of Pharmacovigilance Audits
Auditing remains a cornerstone of building trustworthy PV systems. Regular audits:
- Assess the effectiveness of reporting and data management.
- Identify gaps in compliance with GVP and local regulatory expectations.
- Ensure data integrity and traceability in safety systems.
- Support continuous improvement and inspection readiness.
A strong audit culture is vital for countries transitioning from basic reporting to integrated, proactive PV systems.
How Q&V Supports LMIC Pharmacovigilance Development
At Q&V, we are committed to strengthening global drug safety through expert pharmacovigilance audit, compliance, and capacity-building services.
Our support includes:
- Designing scalable PV systems aligned with GVP and WHO standards.
- Conducting gap assessments for local authorities and marketing authorisation holders.
- Training and mentoring local PV professionals.
- Implementing robust audit frameworks for sustainable compliance and governance.
By building stronger PV systems in LMICs, we create a safer, more equitable global healthcare environment ,one where patient safety truly knows no borders.
Partner with Q&V
Empower your pharmacovigilance systems with global expertise and local understanding.ContactQ&V to strengthen your compliance, audit readiness, and safety governance across all regions.